Adrenocorticotropic hormone

Phase 2Small molecule

Adrenocorticotropic hormone is one of 44 small molecule programs targeting Primary Aldosteronism. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Primary AldosteronismActive, not recruiting

MethylprednisoloneUnknown status

Prostate CancerRecruiting

Primary AldosteronismPreclinical

Active, not recruiting

MethylprednisolonePreclinical

Unknown status

Prostate CancerPhase 2

Recruiting

Competition

Competitive Landscape

348 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Zoladex

TTerSera Therapeutics LLC

Phase 3

35 2

Androgen Deprivation Therapy

Johnson & Johnson

Phase 3

48 3

Rubraca

Bristol-Myers Squibb

Phase 3

9 4

Zejula

GGlaxo Dba Glaxosmithkline

Phase 3

10 5

Acetylsalicylic Acid

Bayer

Phase 3

2 6

Xaluritamig

Amgen

Phase 3

4 7

Perflutren Lipid Microspheres

SSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

Phase 3

1 8

Adrenocorticotropic hormone

Astellas

Phase 2

1 9

Trexall

Jazz Pharmaceuticals

Preclinical

—10

Botox

VVitae Pharmaceuticals Inc., an Allergan affiliate

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2032

Phase 2Recruiting

Prostate Cancer

NCT07005154

Clinical

Trials by Indication[1]

Primary Aldosteronism1 trial

Corticotropin Stimulation in Adrenal Venous Sampling for Patients With Primary Aldosteronism(ADOPA)

Completed·—·N/A·NCT04461535·228 enrolled

Methylprednisolone1 trial

Treatment of Refractory Gout With ACTH or Methylprednisolone

Unknown status·SShanghai 10th People's Hospital·N/A·NCT04808856·60 enrolled

Recovery1 trial

Effects of Acthar on Recovery From Cognitive Relapses in MS

Completed·SState University of New York at Buffalo·Phase 3·NCT02290444·64 enrolled

Proliferative Vitreoretinopathy1 trial

Adrenocorticotropic Hormone (ACTH) for Post-op Inflammation in Proliferative Vitreoretinopathy (PVR)

Completed·JJohns Hopkins University·Phase 1·NCT03727776·11 enrolled

Dermatomyositis1 trial

Acthar in Treatment of Refractory Dermatomyositis and Polymyositis

Completed·RRohit Aggarwal, MD·Phase 2·NCT01906372·12 enrolled

2 more indications

Prostate Cancer1 trial

A Phase 2, Open-label, Multi-cohort Study to Assess the Efficacy and Safety of ASP5541 in Participants With Advanced Prostate Cancer

Recruiting· Astellas logo

Astellas·Phase 2·NCT07005154·218 enrolled

Unspecified1 trial

Adrenocorticotropic Hormone (ACTH) Effects on Myelination in Subjects With MS

Terminated·WWeill Medical College of Cornell University·Phase 4·NCT02446886·15 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Adrenocorticotropic hormone. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Adrenocorticotropic hormone compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Adrenocorticotropic hormone. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Astellas company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Astellas

Adrenocorticotropic hormone

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2032

Trials by Indication[1]

Primary Aldosteronism1 trial

Methylprednisolone1 trial

Recovery1 trial

Proliferative Vitreoretinopathy1 trial

Dermatomyositis1 trial

Prostate Cancer1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News